

To: MGM Hospital-Aurangabad

> N-6, CIDCO Aurangabad -

Contact: 7045919305

Report Of: Mrs. MAYURI AGALE

Pt. Contact:

Sample ID 2300116326 Patient ID 1002356341 Collected on 17/07/2023 Received on 20/07/2023 09:19 Registered on 19/07/2023 18:48 Reported on 20/07/2023 13:47 Referred by DR.ANUPRIYA MAHARSHI

Hemoglobinopathy Screening			
Patient Name: Mrs. MAYURI AGALE	Sample Type: Whole Blood EDTA	1	
Date of Birth/Age: <u>15/01/1993</u>	Gender: FEMALE	City: AURANGABAD	
Method: High Performance Liquid Chromatography (HPLC)	Blood Transfusion History: No		
Referral Reason or Clinical History:			

About the test

Hemoglobinopathy screening by high performance liquid chromatography is a blood test that is used for detecting quantitative and qualitative abnormalities of hemoglobin (Hb), namely, Thalassemia and Structural Hb variants (e.g. HbS) respectively. The test helps identify individuals with these disorders so that they can receive timely and appropriate treatment and care. Antenatal diagnosis of these disorders allows measures to reduce the chances of the birth of an affected baby. It is also possible to screen the newborns for hemoglobinopathies using this approach, thereby decreasing the mortality & morbidity associated with conditions like Sickle cell disorder.

Test findings		
Hb Fraction	Observed Value (%)	Expected Value (%)
HbF	0.4%	<2%
P2*	4.8% ⚠	<4.6%
HbA0	86.2%	85 - 95%
HbA2/HbE	2.8%	1.8 - 3.5%
HbD	ABSENT	Absent
HbS	ABSENT	Absent

^{*}The mentioned P2 value from BioRad Variant-II HPLC system is equivalent of HbA1c value in BioRad D10 system

Indicates that the individual requires further evaluation and opinion from the clinician.

Interpretation

Chromatogram shows normal hemoglobin pattern.

Hemoglobin and PCV are reduced, RBC count is normal and red cell indices are microcytic with high RDW suggesting iron deficiency anemia.

Suggestions

Serum iron studies.

Verified by Mr. Pradip Kadam Incharge Biochemistry

Dr. A. Dasgupta MD, PhD, Consultant Hematopathologist Page 1



of 2



Patient Name: Mrs. MAYURI AGALE Sample ID: 2300116326

HPLC Findings

Patient Data 2300116326 Patient ID: Name: Physician: Sex: DOB: Comments:


Analysis Data Analysis Performed: Injection Number: Run Number: 323 Rack ID: Tube Number:

07/19/2023 13:45:55 0002

Report Generated: Operator ID: 07/19/2023 15:07:06

	Calibrated		Retention	Peak
Peak Name	Area %	Area %	Time (min)	Area
Unknown		0.1	1.01	1857
F	0.4		1.09	8062
Unknown		1.0	1.21	22351
P2		4.8	1.29	109596
P3		4.8	1.70	110388
Ao		86.2	2.34	1986320
A2	2.8		3.62	65126

Total Area: 2,303,699



Analysis comments:

F Concentration = 0.4 A2 Concentration = 2.8

Important Blood Indices	(from CBC Analys	sis)
--------------------------------	------------------	------

Parameters	Result	Reference Range	Units
Hemoglobin (Hb)	11.65 🛕	12 - 15	g/dL
RBC Count	4.31	3.8 - 4.8	x 10 ⁶ /µL
Hematocrit	33.70 🛕	36 - 46	%
Mean Corpuscular Volume (MCV)	78.30 🛕	83 - 101	fL
Mean Corpuscular Hb (MCH)	27.00	27 - 32	pg
Mean Corpuscular Hb Conc. (MCHC)	34.60 🛕	31.5 - 34.5	g/dL
RBC Distribution Width (RDW) (CV)	18.50 🗥	11.6 - 14	%
RBC Distribution Width (RDW) (SD)	47.30 🛕	39 - 46	fL

Notes:

- Recent blood transfusions and iron deficiency can interfere with the results, repeat testing is recommended three months after the last blood transfusion. In case of iron deficiency, it is recommended to evaluate the result post-correction of iron deficiency.
- 2. Megaloblastic anemia can cause elevated HbA2 levels. A repeat assay is recommended after correction of VitB12 deficiency.
- Mild to moderately elevated fetal hemoglobin (HbF) values are observed during pregnancy, hypoxia, chronic kidney disease, use of certain 3. drugs,myelodysplastic syndromes (MDS), aplastic anemia and conditions of stress hemopoiesis.
- Cases with borderline HbA2 levels (3.1-3.9%) could represent Silent Beta-thalassemia trait, or co-existent iron deficiency or Alpha-thalassemia 4 in a case of Beta-thalassemia trait. They need to be investigated further by appropriate tests.
- 5. Confirmatory molecular tests for Beta-thalassemia traits and abnormal hemoglobin disorders (e.g. HbS, HbE, and HbD), followed by subsequent prenatal diagnosis (If required) are available at our centre.
- The mentioned P2 value from BioRad Variant-II HPLC system is equivalent of HbA1c value in BioRad D10 system 6.

Disclaimers:

- The Hb-HPLC is a screening test that detects Beta-thalassemia and other hemoglobin variants. It does not identify Alpha-thalassemia and Silent Beta-thal-assemia carriers. DNA analysis is recommended to rule out Alpha-thalassemia and Silent Beta-thalassemia carriers.
- The result must be interpreted in conjunction with the complete blood counts (CBC), VitB12 and iron profile of the individual. 2.
- 3. Each sample received at Lilac Insights' processing centre is handled with the utmost sensitivity and care. All samples received on Sundays and National holidays are stored as per specific guidelines for the respective specimens and processed on the next day.
- P2 peak in Bio Rad's Variant II HPLC platform represents glycated hemoglobin. It is elevated in uncontrolled diabetes.

Bede Verified by Mr. Pradip Kadam

Incharge Biochemistry

Dr. A. Dasgupta MD, PhD, Consultant Hematopathologist Page 2 of 2